Holen Sie sich die Stockscreener-App
19.27
5.99%
-1.245
Schlusskurs vom Vortag:
$20.52
Offen:
$20.41
24-Stunden-Volumen:
1.15M
Relative Volume:
2.06
Marktkapitalisierung:
$1.14B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.21M
KGV:
-10.20
EPS:
-1.89
Netto-Cashflow:
$-68.53M
1W Leistung:
-6.18%
1M Leistung:
+9.42%
6M Leistung:
-5.16%
1J Leistung:
-21.01%
1-Tages-Spanne:
$17.31
$20.41
1-Wochen-Bereich:
$17.31
$22.07
52-Wochen-Spanne:
$13.30
$25.37
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Firmenname
Enliven Therapeutics Inc
Sektor
Branche
Telefon
720-647-8519
Adresse
6200 LOOKOUT ROAD, BOULDER
Vergleichen Sie ELVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
19.29 | 1.22B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.92 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.15 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.13 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.47 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.88 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Goldman | Buy |
| 2024-12-13 | Eingeleitet | BTIG Research | Buy |
| 2024-09-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-09 | Eingeleitet | Mizuho | Buy |
| 2023-03-29 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Trading the Move, Not the Narrative: (ELVN) Edition - news.stocktradersdaily.com
Enliven Therapeutics: ENABLE trial shows promise in treating atypical fusion CML - Traders Union
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Will Enliven Therapeutics Inc stock benefit from AI adoptionJuly 2025 Setups & Long-Term Capital Growth Strategies - BỘ NỘI VỤ
Affinity Asset Advisors LLC Buys Shares of 400,000 Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) and PreveCeutical Medical (OTCMKTS:PRVCF) Head-To-Head Analysis - Defense World
Can Enliven Therapeutics Inc. stock deliver surprise earnings beatTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - Newser
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - sharewise.com
Ready to Jump After Recent Trade: Enliven Therapeutics Inc (ELVN) - Setenews
Will Enliven Therapeutics Inc. stock keep outperforming rivals2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Is Enliven Therapeutics Inc. stock ready for breakout2025 Volume Leaders & Long-Term Growth Stock Strategies - Newser
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 8%Time to Sell? - MarketBeat
Geode Capital Management LLC Grows Position in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Franklin Resources Inc. Has $8.63 Million Stock Holdings in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Risks Report: Will Enliven Therapeutics Inc. stock benefit from AI adoption2025 Macro Impact & Smart Swing Trading Alerts - BỘ NỘI VỤ
Will Enliven Therapeutics Inc. stock gain from strong economy2025 Fundamental Recap & Weekly Breakout Watchlists - BỘ NỘI VỤ
Does Enliven Therapeutics, Inc. (ELVN) Have the Potential to Rally 87.49% as Wall Street Analysts Expect? - MSN
(ELVN) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Enliven Therapeutics Inc (ELVN) is looking forward to a strong quarter - Setenews
SG Americas Securities LLC Buys 23,261 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics targets CML drug resistance breakthrough - Traders Union
Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $279,125.00 in Stock - MarketBeat
Enliven Therapeutics Insider Sold Shares Worth $279,155, According to a Recent SEC Filing - MarketScreener
Officer Lyssikatos Sells 12,500 ($279.2K) Of Enliven Therapeutics Inc [ELVN] - TradingView
[Form 4] Enliven Therapeutics, Inc. Insider Trading Activity - Stock Titan
Will Enliven Therapeutics Inc. stock outperform international peersWeekly Market Report & AI Enhanced Trade Execution Alerts - newser.com
How Enliven Therapeutics Inc. stock reacts to Fed rate cutsGlobal Markets & Daily Technical Forecast Reports - newser.com
Why Enliven Therapeutics Inc. stock is favored by pension fundsWall Street Watch & Low Drawdown Investment Ideas - newser.com
What hedge fund activity signals for Enliven Therapeutics Inc. stock2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Is Enliven Therapeutics Inc. stock positioned well for digital economyMarket Risk Analysis & Expert-Curated Trade Recommendations - newser.com
Is Enliven Therapeutics Inc. stock a contrarian buy2025 Investor Takeaways & AI Powered Market Entry Ideas - newser.com
Enliven Therapeutics CEO Kintz sells $272k in shares By Investing.com - Investing.com Canada
CEO Kintz Sells 12,500 ($272.7K) Of Enliven Therapeutics Inc [ELVN] - TradingView
Shareholder Lyssikatos Revocable Trust 12/15/11 Files To Sell 12,500 Of Enliven Therapeutics Inc [ELVN] - TradingView
What analyst consensus says on Enliven Therapeutics Inc. stockJuly 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - newser.com
Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Enliven Therapeutics Inc-Aktie (ELVN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER |
Nov 19 '25 |
Sale |
22.33 |
12,500 |
279,155 |
902,688 |
| Kintz Samuel | PRESIDENT AND CEO |
Nov 17 '25 |
Sale |
21.82 |
12,500 |
272,739 |
890,392 |
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):